Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Dynamic human liver proteome atlas reveals functional insights into disease pathways

ABSTRACT: Deeper understanding of liver pathophysiology would benefit from a comprehensive quantitative proteome resource at cell-type resolution. Here, we quantify more than 10,000 proteins and 150,000 sequence-unique peptides across total liver, the major liver cell types, time-course of primary cell cultures and liver disease states. Bioinformatic analysis reveals that half of hepatocyte protein mass is comprised of enzymes and 23% of mitochondrial proteins, twice the proportion of other liver cell types. Using primary cell cultures, we capture dynamic proteome remodeling from tissue states to cell line states, providing useful information for biological or pharmaceutical research. Our extensive data serves as spectral library to characterize a human cohort of non-alcoholic steatohepatitis and cirrhosis. Dramatic proteome changes in liver biopsies include signatures of stellate cell activation resembling liver cirrhosis, providing functional insights.

INSTRUMENT(S): Q Exactive HF-X, Orbitrap Exploris 480

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Kupffer Cell, Endothelial Cell Of Sinusoid, Primary Cell, Hepatocyte, Hepatic Stellate Cell, Liver, Cell Culture

DISEASE(S): Non-alcoholic Steatohepatitis,Liver Cirrhosis

SUBMITTER: Lili Niu

LAB HEAD: Matthias Mann

PROVIDER: PXD027722 | Pride | 2022-05-08

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20171224_QE10_nLC13_LiNi_SA_000001_HliverAtlas_Plate1_10_F1.raw	Raw
	20171224_QE10_nLC13_LiNi_SA_000001_HliverAtlas_Plate1_10_F2.raw	Raw
	20171224_QE10_nLC13_LiNi_SA_000001_HliverAtlas_Plate1_10_F3.raw	Raw
	20171224_QE10_nLC13_LiNi_SA_000001_HliverAtlas_Plate1_10_F4.raw	Raw
	20171224_QE10_nLC13_LiNi_SA_000001_HliverAtlas_Plate1_10_F5.raw	Raw

Items per page:

1 - 5 of 369

Similar Datasets

Transcription profiling of human hepatic and pancreatic stellate cells obtained from tissues of chronic inflammation, and primary or metastatic cancers

Project description:Differences in the expression profile of hepatic and pancreatic stellate cells are investigated. Aim is to identify organ and disease specific transcriptome signatures of stellate cells, comparing hepatic and pancreatic stellate cells obtained from tissues of chronic inflammation, and primary or metastatic cancers of the pancreas. Tissues of chronic pancreatitis (n=6), pancreatic ductal adenocarcinoma (n=5), liver cirrhosis (n=5) and liver metastasis of pancreatic ductal adenocarcinoma (n=6) were collected and stellate cells were isolated by the outgrowth method. Using cDNA microarrays, differentially expressed genes are identified.

2010-01-15 | E-TABM-625 | biostudies-arrayexpress

Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease

Project description:Non-alcoholic fatty liver disease (NAFLD) affects 25% of the population and can progress to cirrhosis, where treatment options are limited. As the liver secrets most of the blood plasma proteins, its diseases should affect the plasma proteome. Plasma Proteome Profiling of 48 patients with cirrhosis or NAFLD, revealed eight significantly changing (ALDOB, APOM, LGALS3BP, PIGR, VTN, IGHD, FCGBP and AFM), two of which are already linked to liver disease. Polymeric immunoglobulin receptor (PIGR) was significantly elevated in both cohorts with a 2.7-fold expression change in NAFLD and 4-fold change in cirrhosis and was further validated in mouse models. Furthermore, a global correlation map of clinical and proteomic data strongly associated DPP4, ANPEP, TGFBI, PIGR, and APOE to NAFLD and cirrhosis. The prominent diabetic drug target DPP4 is an aminopeptidase like ANPEP, ENPEP and LAP3, which all upregulated in the human or mouse data. Furthermore, ANPEP and TGFBI have potential roles in extracellular matrix remodeling in fibrosis. Thus, Plasma Proteome Profiling can identify potential biomarkers and drug targets in liver disease.

2019-03-05 | PXD012056 | Pride

Identification of new therapies based on systems biology approach (DECISION 5)

Project description:GSA from 562 out of 1841 patients with severe decompensated cirrhosis from the DECISION project. The DECISION project aims to discover more personalized combinatorial therapies for patients with decompensation of cirrhosis. This will be achieved by using readily available clinical data, prospectively collected in a homogenous manner from large clinical studies, with the corresponding standardized biobank samples that will produce omics data once they are fully analyzed. The data generated and analyzed in DECISION will directly serve as a basis for accomplishing the objectives of the project, i.e.: 1. Improving our knowledge of the pathophysiology of decompensation of cirrhosis by integrating results of high-throughput multi-omic profiling with comprehensive clinical data from fully characterized patients with available biological samples. 2. Identifying novel combinatorial therapies for patients with decompensation of cirrhosis to prevent death. 3. Developing 2 tests: One predicting the outcome of patients with decompensation of cirrhosis when treated with standard treatment (prognostic test), and the other identifying patients who will respond to the novel combinatorial therapy (test for response).

2024-12-18 | E-MTAB-12555 | biostudies-arrayexpress

Identification of new therapies based on systems biology approach (DECISION 4)

Project description:GSA from 278 out of 1841 patients with severe decompensated cirrhosis from the DECISION project. The DECISION project aims to discover more personalized combinatorial therapies for patients with decompensation of cirrhosis. This will be achieved by using readily available clinical data, prospectively collected in a homogenous manner from large clinical studies, with the corresponding standardized biobank samples that will produce omics data once they are fully analyzed. The data generated and analyzed in DECISION will directly serve as a basis for accomplishing the objectives of the project, i.e.: 1. Improving our knowledge of the pathophysiology of decompensation of cirrhosis by integrating results of high-throughput multi-omic profiling with comprehensive clinical data from fully characterized patients with available biological samples. 2. Identifying novel combinatorial therapies for patients with decompensation of cirrhosis to prevent death. 3. Developing 2 tests: One predicting the outcome of patients with decompensation of cirrhosis when treated with standard treatment (prognostic test), and the other identifying patients who will respond to the novel combinatorial therapy (test for response).

2024-12-18 | E-MTAB-12554 | biostudies-arrayexpress

Identification of new therapies based on systems biology approach (DECISION 3)

Project description:GSA from 387 out of 1841 patients with severe decompensated cirrhosis from the DECISION project. The DECISION project aims to discover more personalized combinatorial therapies for patients with decompensation of cirrhosis. This will be achieved by using readily available clinical data, prospectively collected in a homogenous manner from large clinical studies, with the corresponding standardized biobank samples that will produce omics data once they are fully analyzed. The data generated and analyzed in DECISION will directly serve as a basis for accomplishing the objectives of the project, i.e.: 1. Improving our knowledge of the pathophysiology of decompensation of cirrhosis by integrating results of high-throughput multi-omic profiling with comprehensive clinical data from fully characterized patients with available biological samples. 2. Identifying novel combinatorial therapies for patients with decompensation of cirrhosis to prevent death. 3. Developing 2 tests: One predicting the outcome of patients with decompensation of cirrhosis when treated with standard treatment (prognostic test), and the other identifying patients who will respond to the novel combinatorial therapy (test for response).

2024-12-18 | E-MTAB-12553 | biostudies-arrayexpress

Rat hepatocytes: Advanced cirrhosis vs Control liver, Advanced cirrhosis vs Early cirrhosis

Project description:Gene profiling of hepatocytes in early and advanced cirrhotic Rats Two-condition experiment, Advanced cirrhosis vs Control liver, Advanced cirrhosis vs Early cirrhosis. Biological replicates: 5 Advanced cirrhosis, 5 Early cirrhosis, 5 control liver. Each hepatocyte was isolated independently. One replicate per array.

2011-11-02 | E-GEOD-22977 | biostudies-arrayexpress

Deletion of GSE1 and HDAC1 inactivation alters proteomic profiles and cell cycle control

Project description:The DNA damage response (DDR) is orchestrated by multiple, tightly regulated signalling events. We discovered that genetic suppressor element 1 (GSE1) forms a complex with the histone deacetylation 1 (HDAC1) / CoREST complex and that loss of GSE1 hampers DDR induction. To investigate how GSE1 and HDAC1 can regulate DDR and whether their mode of action might be overlapping, we performed a proteomic analysis using quantitative mass spectrometry based on the TMTpro 16-plex isobaric labelling technology (Li et al., 2020). We determined global acetylome and phosphorylome profiles in the nearly haploid human cell line HAP1 (Andersson et al, 1987) using WT, GSE1 KO and HDAC1 CI backgrounds and compared patterns between untreated and etoposide-treated (0.1 µM, 6 hrs) cells.

2023-10-23 | PXD040339 | Pride

Liver Cirrhosis cohort

Project description:Liver Cirrhosis cohort

| PRJEB38481 | ENA

Chemotherapy and Liver Cirrhosis in Frequently-associated Cancers

Project description:Cirrhosis and cancers of the upper digestive tract, colorectal and ENT share common risk factors. Liver cirrhosis can change the elimination of cancer drugs. Precise data on management and outcome of patients with liver cirrhosis undergoing chemotherapy are lacking. Most patients have been excluded from clinical trials evaluating conventional therapies. The study of tolerance, side effects, and outcome in patients with cirrhosis could help improve chemotherapy management for better tolerance and efficacy. The main objective is to estimate the frequency of liver cirrhosis among patients evaluated in CPR for ENT, upper digestive or colorectal cancer. Secondary objective includes the evaluation ofthe impact of cirrhosis on the management of chemotherapy by comparing cirrhotic patients’ outcomes with a control group of matched non-cirrhotic patients.

| 2323209 | ecrin-mdr-crc

Rattus norvegicus, Mus musculus

Project description:Cirrhosis and liver failure

| PRJNA949711 | ENA